For now and the coming days it makes sense for CRIS to run up to $3 and stays there until we get further news on the new IND and clinical trials. Erivedge has big potential and can alone take CRIS to $10 a share. That is why CURIS may be bought out.
That's a good thought, but I don't think a rise in the volume and PPS has anything to do with Erivedge. Curis has been busy patenting allot of stuff in reference to proteins this year. I think they may have stumbled onto a major breakthrough in their science. Research their patents and see if you agree.